Familiar fixes for a modern malady: a discussion on the possible cures of COVID-19

Familiar fixes for a modern malady: a discussion on the possible cures of COVID-19

The SARS-CoV-2 virus emerged in December 2019 in Wuhan, China and then spread rapidly all over the world. Scientists are intensifying their research efforts in order to find antivirals specific to the virus and vaccines to treat or prevent COVID-19. Now, for a medicative cure for COVID-19, several d...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteur:	Amrit Krishna Mitra
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	AIMS Press 2020-12-01
Reeks:	AIMS Molecular Science
Onderwerpen:	covid-19 sars-cov-2 chloroquine hydroxychloroquine lopinavir ritonavir remdesivir favipiravir vitamin c convalescent plasma
Online toegang:	http://www.aimspress.com/article/10.3934/molsci.2020012?viewType=HTML

Gelijkaardige items

Review of Clinical Trials in COVID-19: Trying to Solve the Clinicians’ Conundrum
door: Amita Athavale, et al.
Gepubliceerd in: (2020-07-01)

COVID-19: An Update about the Discovery Clinical Trial
door: Jean Jacques Vanden Eynde
Gepubliceerd in: (2020-05-01)

Therapeutic Strategies in the Management of COVID-19
door: Rajashri R. Naik, et al.
Gepubliceerd in: (2021-02-01)

A narrative review of antiviral drugs used for COVID-19 pharmacotherapy
door: Subodh Kumar, et al.
Gepubliceerd in: (2021-01-01)

COVID-19: A Brief Overview of the Discovery Clinical Trial
door: Jean Jacques Vanden Eynde
Gepubliceerd in: (2020-04-01)

A Comparative Study of Approved Drugs for SARS-CoV-2 by Molecular Docking
door: Achal Mishra, et al.
Gepubliceerd in: (2021-06-01)

COVID-19 possible medical treatments
door: Marzieh Mohammadi, et al.
Gepubliceerd in: (2021-01-01)

Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19)
door: Abhi Bhadra, et al.
Gepubliceerd in: (2020-05-01)

Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
door: Shahamah Jomah, et al.
Gepubliceerd in: (2020-09-01)

Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis
door: Sultan Ayoub Meo, et al.
Gepubliceerd in: (2020-10-01)

Comparison of effectiveness of various treatment strategies in COVID-19 patients: A Systematic Review
door: Muhammad Shehryar Hussain, et al.
Gepubliceerd in: (2020-08-01)

Pharmacological management of COVID-19
door: Veena Raghunathan, et al.
Gepubliceerd in: (2020-01-01)

An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
door: A. S. Kolbin
Gepubliceerd in: (2020-05-01)

Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
door: B. K. Romanov
Gepubliceerd in: (2020-09-01)

Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
door: Xinni Xu, et al.
Gepubliceerd in: (2020-05-01)

The Rationale for Potential Pharmacotherapy of COVID-19
door: Maha Saber-Ayad, et al.
Gepubliceerd in: (2020-05-01)

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
door: Qomara WF, et al.
Gepubliceerd in: (2021-11-01)

Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities
door: Milo Gatti, et al.
Gepubliceerd in: (2021-02-01)

Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study
door: David Grimaldi, et al.
Gepubliceerd in: (2020-10-01)

COVID-19 treatment in children: A systematic review and meta-analysis
door: Prateek Kumar Panda, et al.
Gepubliceerd in: (2021-01-01)

Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
door: Alina Kröker, et al.
Gepubliceerd in: (2021-11-01)

Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations
door: Stanković Biljana, et al.
Gepubliceerd in: (2020-01-01)

Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
door: Hayato Koba, et al.
Gepubliceerd in: (2020-12-01)

Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications
door: Abubakar AR, et al.
Gepubliceerd in: (2020-12-01)

Clinical evaluation of selected Pharmacological Treatments used for Coronavirus (COVID-19) pandemic
door: hasan mohammed altemimy
Gepubliceerd in: (2020-06-01)

Efficacy of lopinavir/ritonavir plus interferon beta compared to hydroxychloroquine in the treatment of COVID-19: A retrospective observational study
door: Motahareh Amirizadeh, et al.
Gepubliceerd in: (2023-01-01)

High Prevalence of Potential Drug-Drug Interactions Among Patients Treated with Off-label Therapies for COVID-19
door: Allan Ramos-Esquivel, et al.
Gepubliceerd in: (2022-06-01)

Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents
door: Shagun B Shah, et al.
Gepubliceerd in: (2021-01-01)

Progress in the Research and Development of Anti-COVID-19 Drugs
door: Lianzhou Huang, et al.
Gepubliceerd in: (2020-07-01)

A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial
door: A. Abayomi, et al.
Gepubliceerd in: (2021-12-01)

Measuring the energy for the molecular graphs of antiviral agents: Hydroxychloroquine, Chloroquine and Remdesivir
door: Muhammad Haroon Aftab, et al.
Gepubliceerd in: (2024-01-01)

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
door: Mehdi Hassaniazad, et al.
Gepubliceerd in: (2020-10-01)

Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as MPro inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
door: Woon Yi Law, et al.
Gepubliceerd in: (2020-11-01)

The Effectiveness of Hydroxychloroquine Versus Hydroxychloroquine Plus Lopinavir/Ritonavir Therapy in SARSCoV- 2 Pneumonia
door: Ayşe BATIREL, et al.
Gepubliceerd in: (2021-12-01)

Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study
door: Min Joo Choi, et al.
Gepubliceerd in: (2021-01-01)

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial
door: Justin T. Denholm, et al.
Gepubliceerd in: (2020-07-01)

Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations
door: Paolo Gaibani, et al.
Gepubliceerd in: (2021-03-01)

Cardiotoxic Drugs Used in the Treatment of COVID-19
door: A. S. Zmitrukevich, et al.
Gepubliceerd in: (2024-01-01)

Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children
door: Nils von Hentig, et al.
Gepubliceerd in: (2021-05-01)

Scoping insight on antiviral drugs against COVID-19
door: Ahmed S. Ali, et al.
Gepubliceerd in: (2021-10-01)